Hims & Hers Health Inc was upgraded to “Neutral” from “Underperform” by Bank of America, which said a new agreement with Novo Nordisk removes a key legal risk that had weighed on the telehealth ...
Futures are trading lower as many across Wall Street breathed a semi-sigh of relief yesterday after oil futures, which shot up to $120 overnight, retreated below $100 on Monday. That was the biggest ...
On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (HIMS +5.89%), an estimated $18.07 million trade based on quarterly ...
Hims & Hers received a flurry of upgrades, though most analysts are opting to stay on the sidelines. Here’s why.
With hundreds of millions of people turning to chatbots for advice, it was only a matter of time before tech companies began offering programs specifically designed to answer health questions. Wyoming ...
Stocks making the biggest moves midday: Rivian, Hims & Hers, BioNTech, Vertex Pharmaceuticals & more
Check out some of the companies making the biggest moves midday: Hims & Hers Health — Shares of the telehealth company jumped 3%. Bank of America upgraded the stock to neutral from underperform after ...
Amid the company’s efforts to resolve issues raised during an FDA inspection early last year, Novo Nordisk’s operating base in Plainsboro, New Jersey—already the recipient of a recent Form 483—has ...
Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, payers and other industry players look to expand their businesses and gain a competitive edge. | CHS' ...
As the Super Bowl approached halftime, Hims & Hers publicly staked its claim to preventive medicine in front of the American people. In a one-minute ad, the direct-to-consumer health company ...
Whether President Trump signaled that he may soon end the military strikes is weighing on the minds of investors, executives and others.
Novo Nordisk and Hims & Hers have reached a deal that, for now, appears to end their bitter dispute around Hims’ sale of compounded versions of Novo’s blockbuster obesity drug Wegovy.
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk's branded weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results